Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 352

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 352
---
-current portion           30,957      30,957      30,957  
  Financial liabilities—current portion                8,936       8,936       8,936  
  Trade payables and others                           17,018      17,018      17,018  
  Total financial liabilities                         56,911      56,909      56,909  

F-71

  As of December 31, 2024 (in thousands of euro)                                                    
 ────────────────────────────────────────────────────────────────────────────────────────────────────
  Financial assets                                                                                  
  Non-current financial assets                         10,281      10,281                   10,281  
  Trade receivables and others                         14,300                  14,300       14,300  
  Short-term investments                               14,374      14,374                   14,374  
  Cash and cash equivalents                            66,396      66,396                   66,396  
  Total financial assets                              105,351      91,051      14,300      105,351  

  As of December 31, 2024 (in thousands of euro)                                      
 ──────────────────────────────────────────────────────────────────────────────────────
  Financial liabilities                                                               
  Financial liabilities—non-current portion           22,286      22,286      22,286  
  Financial liabilities—current portion                8,709       8,709       8,709  
  Trade payables and others                           16,007      16,007      16,007  
  Total financial liabilities                         47,002      47,002      47,002  

(1) The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements.

(2) The fair value of financial assets classified as fair value through comprehensive income corresponds to the market value of the assets, which are primarily determined using level 1 measurements.

(3) The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.

In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchy of methods used to determine fair value:

Level 1: fair value determined based on quoted prices in active markets for assets or liabilities;

Level 2